Drugs / RISLENEMDAZ
RISLENEMDAZ
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 2 missed | ||||||
| Phase 1 | NCT00472576 | May 2007 → Aug 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | Missed primary |
| Phase 1 | NCT00505843 | May 2007 → Feb 2008 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT02459236 | Jun 2015 → Sep 2016 | major depressive disorder | Avalo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01941043 | Nov 2013 → Sep 2014 | major depressive disorder | Avalo Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2019-07-01 | Avalo Therapeutics, Inc. | Results Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH) July 01, 2019 6:30am EDT avalotx.com ↗
These final results further strengthen the previously reported interim results, showing that CERC-301 produces a rapid, robust and sustained improvement in systolic blood pressure (SBP) upon standing in Parkinson’s patients suffering from nOH, utilizing the standardized Orthostatic Standing Test (OST). |
| 2019-04-15 | Avalo Therapeutics, Inc. | Results Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH) April 15, 2019 6:30am EDT avalotx.com ↗
The top-line results demonstrate a rapid, robust increase in systolic blood pressure (SBP) from baseline to 6 hours. |
| 2016-11-29 | Avalo Therapeutics, Inc. | Results Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder November 29, 2016 4:01pm EST avalotx.com ↗
Overall, the trial failed to demonstrate efficacy on the primary endpoint for mean improvement in Bech-6, a subset of the Hamilton Depression Scale (HDRS-17), averaged over days 2 and 4 post dose. |
| 2016-01-19 | Avalo Therapeutics, Inc. | Results Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model January 19, 2016 9:10am EST avalotx.com ↗
This publication reports results of CERC-301 in an acute preclinical depression model known as the forced swim test, a common model of antidepressant efficacy. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RISLENEMDAZ | ChEMBL registry synonym — accepted as the source's own label CHEMBL2068839 ↗ |
| Known as | CERC-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01941043 ↗ |
| Known as | MK-0657 | “Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate...” PMID 19491335 ↗ Jun 2009 |
| Action | Inhibit | “selective NR2B antagonist (MK-0657, 4-8 mg/day given orally)” NCT00472576 ↗ |
| Modality | Small molecule | — CHEMBL2068839 ↗ |
| Route | Oral | “MK-0657, 4-8 mg/day given orally” NCT00472576 ↗ |